As aging population demographics and managed care initiatives drive growth in home health care and self-administration of drug therapies for chronic conditions such as diabetes, arthritis, and hormone replacement therapy, drug developers are showing increased interest in routes of administration that are patient-friendly and cost-effective. Intranasal administration is well positioned to take advantage of these trends and evolve into a significant role in the future of pharmaceutical development and commercialization. Intranasal delivery will grow at the expense of the predominant drug delivery methods (oral and parenteral), which cannot be readily optimized for the delivery and dosing of a significant portion of biologically derived drug substances.

Publication Date: July 2007